- WuXi XDC has been named “Best CDMO” for the third consecutive year and “Best CRO” at the 2025 World ADC Awards, the only company to receive two honours this year.
- The recognition reflects the company’s strength in delivering one-stop CRDMO services, technological innovation, and leadership in the global bioconjugates sector.
WuXi XDC Cayman Inc., a global Contract Research, Development and Manufacturing Organisation (CRDMO) specialising in bioconjugates, has been named the winner of “Best CDMO” for the third year in a row and “Best CRO” at the 2025 World ADC Awards. It was the only service company to receive two awards at this year’s event.
The accolades recognise WuXi XDC’s end-to-end service model and innovative research capabilities, affirming its position as a leading provider in the global bioconjugate field. The World ADC Awards celebrate companies and teams that have made outstanding contributions to antibody-drug conjugate (ADC) research, development, and commercialisation.
“We are deeply honoured and encouraged to be named the winner of ‘Best CDMO’ for the third time and the winner of ‘Best CRO’ for the first time,” said Dr Jimmy Li, CEO of WuXi XDC. “The honours represent high recognition from the global industry and our customers, and serve as a milestone in our team’s unwavering pursuit of innovation and excellence.”
WuXi XDC offers integrated CRDMO solutions encompassing research, process development, and manufacturing. The company’s proprietary technologies — including WuXiDARx™, X-LinC, and WuXiTecan payload linker platforms — are designed to streamline conjugation processes, enhance efficiency, and lower production costs for antibody-drug conjugates (ADCs) and other bioconjugate modalities.
According to the company’s 2025 interim report, WuXi XDC now serves 563 global customers, has supported nearly 100 IND applications, and partners with 13 of the world’s top 20 pharmaceutical companies. The company holds an estimated 22% global market share in the bioconjugate CRDMO sector, reflecting its continued leadership in contract manufacturing and development for next-generation therapeutics.
